Search results
Chih-Hsin Hsu Aims The Registry to Evaluate Early and Long‐Term PAH Disease Management (REVEAL) risk scores differentiate survivals in patients with pulmonary arterial hypertension (PAH).
- Medical Doctor
Chih-Hsin HSU, Medical Doctor | Cited by 301 | of National...
- Medical Doctor
Chih-Hsin HSU, Medical Doctor | Cited by 301 | of National Cheng Kung University, Tainan (NCKU) | Read 19 publications | Contact Chih-Hsin HSU
Hsu,Chih-Hsin Deputy Superintendent and Professor and Attending Physician of Internal Medicine; PhD, Insitute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan Master Degree, Pulmonary Vascular Disease, University of Bologna, Italy
Dr. Hsu specializes in QM online course design & review, guiding capstone courses and doctoral dissertations, teacher education, intercultural communication, and ESL & biliteracy instruction. She has almost two decades of teaching experience in the United States and abroad from middle school through doctoral levels.
Chih-Hsin, Hsu. Deputy Superintendent and Professor and Attending Physician of Internal Medicine. PhD, Insitute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan Master Degree, Pulmonary Vascular Disease, University of Bologna, Italy Medical Doctor ,China Medical College, Taichung ,Taiwan.
Sep 30, 2021 · Pulmonary artery hypertension (PAH) pathology involves extracellular matrix (ECM) remodeling in cardiac tissues, thus promoting cardiac fibrosis progression. miR-29a-3p reportedly inhibits lung progression and liver fibrosis by regulating ECM protein expression; however, its role in PAH-induced fibrosis remains unclear.
Since the discovery of three major pathophysiological mechanisms of pulmonary arterial hypertension (PAH), including prostacyclin, endothelin and nitric oxide pathways, the therapeutic options for PAH have increased. Nevertheless, despite these advances, the prognosis remains unsatisfactory for many ….
